RUNX3 has been shown to be a prognostic biomarker for a variety of cancers, including breast, gastric, colorectal, and ovarian cancer, and there is a negative correlation of RUNX3 inactivation and patient survival [23,77,78]. This evidence concerns the gene RUNX3 and ovarian carcinoma.